BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 91 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2017. The put-call ratio across all filers is 0.10 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $249,000 | -61.9% | 1,706 | -63.7% | 0.00% | -71.4% |
Q3 2021 | $653,000 | +12.2% | 4,700 | -21.7% | 0.01% | +16.7% |
Q2 2021 | $582,000 | -33.8% | 6,000 | -55.6% | 0.01% | -64.7% |
Q3 2020 | $879,000 | +42.0% | 13,525 | +19.0% | 0.02% | +13.3% |
Q4 2019 | $619,000 | -84.6% | 11,361 | -88.2% | 0.02% | -87.3% |
Q3 2019 | $4,026,000 | +1543.3% | 96,500 | +1623.2% | 0.12% | +1211.1% |
Q2 2019 | $245,000 | -55.1% | 5,600 | -47.2% | 0.01% | -52.6% |
Q1 2019 | $546,000 | -92.3% | 10,600 | -94.5% | 0.02% | -93.1% |
Q4 2018 | $7,123,000 | +97.0% | 192,600 | +100.0% | 0.27% | +70.2% |
Q3 2018 | $3,616,000 | +19.0% | 96,300 | -18.3% | 0.16% | -29.4% |
Q1 2018 | $3,038,000 | +426.5% | 117,919 | +451.2% | 0.23% | +385.1% |
Q4 2017 | $577,000 | – | 21,394 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |